Axogen (AXGN) news
Recent news
Axogen, Inc.: H.C. Wainwright raises target price to $53 from $50
AInvest Wire · Jul 30, 2026AxoGen completes BLA submission to FDA for Avance Nerve graft
AxoGen completes BLA submission to FDA for Avance Nerve graft AxoGen, Inc. (AXGN), a leading innovator in peripheral nerve injury solutions, recently initiated the rolling submission process for a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for its Avance…
AInvest Wire · Sep 6, 2024ImportantAxogen Shares Fall 13% on Lukewarm 2024 Outlook
Axogen Shares Fall 13% on Lukewarm 2024 Outlook Axogen, a leading regenerative medicine company specializing in the development, manufacturing, and commercialization of innovative surgical solutions, experienced a significant drop in shares by 13% on February 9, 2023, due to a lukewarm 2024 outlook…
AInvest Wire · Mar 5, 2024ImportantAxogen Shares Rise, Company Says Clinical Trial of Axoguard Nerve Cap Met Primary Endpoint
Axogen Shares Rise, Company Says Clinical Trial of Axoguard Nerve Cap Met Primary Endpoint Axogen, a leading provider of surgical solutions for peripheral nerve injuries, recently announced positive topline results from a clinical trial of Axoguard Nerve Cap, a product designed to treat peripheral…
AInvest Wire · Jan 18, 2024Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.